ORIGINAL ARTICLE

Retrospective Study

Smaller tumor size is associated with poor survival in T4b colon cancer

Ben Huang, Yang Feng, Shao-Bo Mo, San-Jun Cai, Li-Yong Huang

Ben Huang, Yang Feng, Shao-Bo Mo, San-Jun Cai, Li-Yong Huang, Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 20032, China

Abstract

AIM: To hypothesize that in patients with colon cancer showing heavy intestinal wall invasion without distant metastasis (T4bN0-2M0), small tumor size would correlate with more aggressive tumor behaviors and therefore poorer cancer-specific survival (CSS).

METHODS: We analyzed T4bN0-2M0 colon cancer patients in the Surveillance, Epidemiology and End Results (SEER) database. A preliminary analysis of T4bN0-2M0 colon cancer patients at the Fudan University Shanghai Cancer Center is also presented.

RESULTS: A total of 1734 T4bN0-2M0 colon cancer patients from the SEER database were included. Kaplan-Meier analysis revealed decreasing CSS with decreasing tumor size ($P < 0.001$). Subgroup analysis showed a significant association between poorer CSS with smaller tumor size in T4bN0 patients ($P = 0.024$), and a trend of association in T4bN1 ($P = 0.182$) and T4bN2 patients ($P = 0.191$). Multivariate analysis identified tumor size as an independent prognostic factor for CSS in T4bN0-2M0 patients ($P = 0.024$). Preliminary analysis of Fudan University Shanghai Cancer Center samples suggested the 5-year CSS was 50.0%, 72.9% and 77.1% in patients with tumors ≤ 4.0 cm, 4.0-7.0 cm and ≥ 7.0 cm.

CONCLUSION: Smaller tumor size is associated with poorer CSS in the T4bN0-2M0 subset of colon cancer, particularly in the T4bN0M0 subgroup.

Key words: Survival; Colon cancer; Tumor size; T4b colon cancer; Locally advanced colon cancer

Core tip: In contrast to the association of larger tumor size with poor cancer-specific survival (CSS) in colon cancer patients overall, this study suggested that smaller tumor size was associated with poor CSS in the T4bN0-2M0 subpopulation, particularly in the T4bN0M0 subgroup.

INTRODUCTION

Locally advanced colorectal cancer, including T4b colorectal cancer, accounts for 5%-22% of all colorectal cancer cases[1]. Several prognostic factors have been identified for locally advanced colorectal cancer, including pN+[1,2], pT4[1-3], poor tumor differentiation[2], high serum CEA[2,4], and lymphovascular or perineural invasion[1,5]. T4b lesions (previously classified as T4) are associated with poorer prognosis when they are invasive or when they adhere to other organs or structures[3,6,7].

Standard surgical treatment for such patients is multivisceral resection (MVR), which refers to *en bloc* removal of the tumor and infiltrated organs in order to achieve margin-negative (R0) resection[8,9]. This procedure is associated with increased incidence of a wide variety of complication[9-11], and it is often impossible to distinguish malignant invasion from inflammatory adhesions intraoperatively[12]. Thus, identifying novel risk factors in such patients might allow a more appropriate adjuvant treatment planning and a better assessment of the long-term prognosis after the MVR.

Smaller tumor size is generally associated with greater cancer-specific survival (CSS) in patients with colon cancer[13-15]. However, analysis of subgroups of colon cancer patients has produced surprising results. In a study of 610 Japanese colon cancer patients, Takahashi *et al*[16] found CSS to be lower with smaller tumors: patients with tumors 4-8 cm in size showed an HR of 0.45 (95%CI: 0.293-0.696, *P* < 0.001) relative to patients with tumors < 4 cm. Similarly, a study of stage ⅡA colon cancer[17] found decreased CSS with smaller tumor size.

We hypothesized that small tumor size would be associated with more aggressive tumor behavior and thus lower CSS in the subgroup of colon cancer patients with heavy intestinal wall invasion (T4bN0-2) without distal metastasis (M0). To address this hypothesis, we analyzed patients with T4bN0-2M0 colon cancer in the US Surveillance, Epidemiology and End Results (SEER) database. Subgroup analysis was conducted separately for patients in the T4bN0, T4bN1, and T4bN2 stages. We also carried out a preliminary analysis of the 101 patients with T4bN0-2M0 colon cancer receiving surgical treatment at the Fudan University Shanghai Cancer Center (FUSCC).

MATERIALS AND METHODS

Selection of patients from the SEER database
The SEER database is a population-based cancer registry that collects and publishes cancer incidence and survival data from 18 population-based cancer registries covering approximately 26% of the US population. Cases of invasive colon cancer from January 1988 to December 2003 were extracted from the database (http://seer.cancer.gov, April 2013 release). For inclusion in our study, subjects had to meet the following criteria: (1) age between 18 and 75 years at time of diagnosis; (2) diagnosis of adenocarcinoma, mucinous adenocarcinoma or signet-ring carcinoma of the colon in AJCC stages T4bN0-2; (3) known maximum tumor diameter, depth of invasion, and lymph node status; (4) at least 12 harvested lymph nodes; (5) colon cancer surgically resected; (6) confirmation of diagnosis based on pathology of a surgical specimen, rather than based on death certificate or autopsy; (7) non-metastatic (AJCC stage M0); (8) known survival time and cause of death; and (9) colon cancer as the only malignant tumor. Subjects who underwent neoadjuvant chemoradiotherapy (CRT) or only local tumor excision were excluded.

Selection of patients from the FUSCC
The FUSCC colorectal cancer database was established in January 2006, and prospectively collects data of colorectal cancer patients receiving treatment at FUSCC. Data were extracted for T4bN0-2M0 colon cancer patients treated between 2006 and 2012 with radical surgery and 6 mo of adjuvant chemotherapy involving either the combination of oxaliplatin and fluorouracil/folinic acid or the combination of oxaliplatin and oral capecitabine. The inclusion and exclusion criteria were identical to that in the data selection from the SEER database. The FUSCC Ethical Committee and Institutional Review Board approved the research protocol, and all subjects provided written informed consent.

Outcome measures
We collected data on the following variables from the SEER database: gender, race, patient age at diagnosis (with 60 years applied as a cut-off in analyses), primary site, number of primary tumors, year of diagnosis, histological type, pathology grade, tumor size, TNM stage, number of lymph nodes harvested

Table 1 Demographics of patients from the Surveillance, Epidemiology and End Results database with T4bN0-2M0 colon cancer, stratified by tumor size *n* (%)

Characteristic	Tumor size (cm)				*P* value
	Total (*n* = 1734)	≤ 4.0 (*n* = 274)	4.0-7.0 (*n* = 653)	≥ 7.0 (*n* = 807)	
Median follow-up (mo)	43	33	43	50	
IQR	15-107	12-92	17-105	14-114	
Sex					0.395
Male	857 (49.4)	131 (47.8)	313 (47.9)	413 (51.2)	
Female	877 (50.6)	143 (52.2)	340 (52.1)	394 (48.8)	
Year of diagnosis					0.867
1988-1999	856 (49.4)	137 (50.0)	317 (48.5)	402 (49.8)	
2000-2003	878 (50.6)	137 (50.0)	336 (51.5)	405 (50.2)	
Age at diagnosis (yr)					0.330
≤ 60	785 (45.3)	130 (47.4)	281 (43.0)	374 (46.3)	
> 60	949 (54.7)	144 (52.6)	372 (57.0)	433 (53.7)	
Primary site					0.187
Right colon	1103 (63.6)	176 (64.2)	398 (60.9)	529 (65.6)	
Left colon	631 (36.4)	98 (35.8)	255 (39.1)	278 (34.4)	
Race					0.145
White	1386 (80.0)	212 (77.4)	530 (81.2)	644 (79.8)	
Black	195 (11.2)	41 (15.0)	61 (9.3)	93 (11.5)	
Other[1]	153 (8.8)	21 (7.6)	63 (9.5)	69 (8.7)	
Histological type					0.016
Adenocarcinoma	1351 (77.9)	223 (81.4)	525 (80.4)	603 (74.7)	
Mucinous adenocarcinoma	341 (19.7)	42 (15.3)	118 (18.1)	181 (22.4)	
Signet-ring cell carcinoma	42 (2.4)	9 (3.3)	10 (1.5)	23 (2.9)	
Pathology grade					0.001
High/Moderate	1158 (66.8)	189 (69.0)	466 (71.4)	503 (62.3)	
Poor/Undifferentiated	576 (33.2)	85 (31.0)	187 (28.6)	304 (37.7)	
N stage					0.001
N0	725 (41.8)	93 (34.0)	255 (39.0)	377 (46.7)	
N1	460 (26.5)	74 (27.0)	188 (28.8)	198 (24.5)	
N2	549 (31.7)	107 (39.0)	210 (32.2)	232 (28.8)	
LNH					0.013
≤ 18	938 (54.1)	157 (57.3)	375 (57.4)	406 (50.3)	
> 18	796 (45.9)	117 (42.6)	278 (42.6)	401 (49.7)	

[1]Includes Native American, Asian, Pacific Islander and Unknown. IQR: Interquartile range; LNH: Number of lymph nodes harvested.

(with 18 applied as the cut-off in analyses), number of metastatic lymph nodes (N0, N1, or N2), radiation sequence with surgery, survival time and cause of death. The same data were collected from the FUSCC dataset, from which we also collected information on lymphovascular invasion and perineural invasion. All cases were restaged according to the 7th edition of the AJCC Cancer Staging Manual.

Tumor size was defined as the maximal tumor diameter obtained from pathology reports on resected cancer specimens. Tumor size cut-off points to assign patients to high-, medium-, or low-risk groups were identified using X-tile software (www.tissuearray.org/rimmlab)[18]. In X-tile, data are shown in a triangular grid, with each point in the grid representing a potential cut-off point. The intensity of the color in the grid represents the strength of the association between tumor size and CSS. The primary study outcome was CSS. CSS was calculated from the date of diagnosis to the date of colon cancer-specific death. Cases were censored if patients died from other causes or were alive at the time of last follow-up.

Statistical analysis
Cut-off points for CSS were determined based on minimal *P* values from log-rank χ^2 statistics using X-tile. Groups with different tumor sizes, defined using the cut-off points determined by X-tile, were compared in terms of patient- and disease-related characteristics using χ^2 tests. Survival data were plotted as Kaplan-Meier curves and compared using log-rank tests. A multivariate Cox regression model was used to analyze risk factors for survival outcomes. All computed *P* values were 2-tailed, and statistical significance was accepted at *P* < 0.05. All analyses were performed using SPSS 20.0.

RESULTS

Descriptive statistics in the SEER dataset
A total of 1734 patients (857 men and 877 women) in the SEER database were included in the final analysis, of whom 978 (56.4%) were recorded as having died from colon cancer. Patient demographics and pathology features stratified by tumor size are shown in Table

Figure 1 Frequency distribution of T4bN0-2M0 colon cancer patients from the Surveillance, Epidemiology and End Results database, according to tumor size. The most frequent tumor size was 6 cm.

| Cut-off	*n*	5-yr CSS	Log-rank χ^2	*P* value
≤ 3	94	35.9%	3.710	0.054
> 3	1640	48.7%		
≤ 4	274	37.1%	15.214	< 0.001
> 4	1460	50.0%		
≤ 5	542	40.8%	18.235	< 0.001
> 5	1192	51.2%		
≤ 6	845	43.3%	14.118	< 0.001
> 6	889	52.4%		
≤ 7	1066	45.1%	7.303	0.007
>7	668	52.5%		
≤ 8	1284	46.3%	3.877	0.049
> 8	450	52.5%		
≤ 9	1422	46.9%	2.270	0.132
> 9	312	52.8%		
≤ 10	1541	47.0%	5.061	0.024
> 10	193	55.8%		

Table 2 Univariate analyses of patients from the Surveillance, Epidemiology and End Results database with T4bN0-2M0 colon cancer, stratified by tumor size

Figure 2 X-tile plots of tumor size in the Surveillance, Epidemiology and End Results cohort of patients with T4bN0-2M0 colon cancer. The x-axis represents all potential tumor size cut-off values from low to high (left to right) that could be used to define the low subset, while the y-axis represents all potential cut-off values from high to low (top to bottom) that could be used to define the high subset. Brighter pixels indicate stronger association between tumor size and CSS. The plot showed the brightest pixel (marked by the black circle) when the study cohort was divided into high, middle, and low subsets using cut-off points of 4.0 and 7.0 cm. Green coloration indicates continuous direct association between increasing tumor size and higher CSS. CSS: CANCER-specific survival.

1. Median follow-up time was 43 mo (interquartile range, 15-107 mo). Most subjects were Caucasian (80.0%), followed by African-Americans (11.2%). Histology types included adenocarcinoma (77.9%), mucinous cancer (19.7%), and signet ring cell cancer (2.4%). Lymph node status included N0 (no lymph node involvement), 41.8%; N1 (1-3 metastasized lymph nodes), 26.5%; and N2 (> 3 metastasized lymph nodes), 31.7%. The proportions of patients with lymph node metastasis (N1 or N2) were 66.0% in the subgroup with tumors ≤ 4.0 cm, 61.0% in the subgroup with tumors 4.0-7.0 cm, and 53.3% in the subgroup with tumors ≥ 7.0 cm (*P* = 0.001). The distribution of patients with T4bN0-2M0 colon cancer among the tumor size subgroups is shown in Figure 1.

Tumor size vs CSS in the SEER dataset

Several Kaplan-Meier analyses of T4bN0-2M0 patients were conducted using tumor size cut-off points ranging from 3 to 10 cm. In all analyses, patients with smaller tumor size showed poorer CSS than those with larger tumor size at each cut-off point tested. As the cut-off point increased, so did the survival rate of patients with tumors smaller than that cut-off (Table 2). X-tile analysis identified 4.0 and 7.0 cm as optimal cut-off values (Figure 2).

Using 4.0 and 7.0 cm as cut-off values, Kaplan-Meier analysis showed decreasing CSS with decreasing tumor size (*P* < 0.001): 5-year CSS was 37.1% in patients with tumors ≤ 4.0 cm, 47.0% in patients with tumors 4.0-7.0 cm and 52.5% in those with tumors ≥ 7.0 cm (Figure 3A). Univariate analysis of all subjects suggested the following risk factors: age at diagnosis (*P* < 0.001), histology type (*P* < 0.001), pathology grade (*P* < 0.001), primary site (*P* = 0.001), tumor

A

B

C

D

Figure 3 Kaplan-Meier curves for colon cancer patients from the Surveillance, Epidemiology and End Results database, stratified by tumor size. A: T4bN0-2M0 group; B: T4bN0M0 subgroup; C: T4bN1M0 subgroup; D: T4bN2M0 subgroup. Survival rate decreased significantly with decreasing tumor size in the case of T4bN0-2 patients ($P < 0.001$). In subgroup analysis, survival rate decreased significantly with decreasing tumor size in T4bN0 patients ($P = 0.024$), but this association was not significant for T4bN1 ($P = 0.182$) or T4bN2 ($P = 0.191$) patients.

size ($P < 0.001$), number of lymph nodes harvested ($P = 0.001$) and N stage ($P < 0.001$). Multivariate Cox proportional modeling identified the following independent prognostic factors: age at diagnosis ($P < 0.001$), pathology grade ($P = 0.002$), tumor size ($P = 0.024$), number of lymph nodes harvested ($P = 0.009$), and N stage ($P < 0.001$). Relative to patients with tumors $\leqslant 4.0$ cm, patients with tumors 4.0-7.0 cm were more likely to show greater CSS (HR = 0.820, 95%CI: 0.683-0.985, $P = 0.034$), as were patients with tumors $\geqslant 7.0$ cm (HR = 0.775, 95%CI: 0.645-0.932, $P = 0.007$) (Table 3).

Kaplan-Meier analysis based on N stage showed decreasing CSS with increasing N stage ($P < 0.001$), the 5-year CSS was 69.5% in T4bN0 patients, 43.7% in T4bN1 patients and 22.6% in T4bN2 patients. Subgroup analysis confirmed the inverse relationship between tumor size and CSS in T4bN0 patients ($P = 0.024$; Figure 3B). The 5-year CSS was 58.4% in patients with tumors $\leqslant 4.0$ cm, 69.3% in patients with tumors 4.0-7.0 cm and 72.4% in those with tumors

$\geqslant 7.0$ cm. In contrast, the corresponding 5-year CSS rates were 35.8%, 42.5% and 47.9% in the subgroup of T4bN1 patients, suggesting that tumor size was not significantly associated with CSS ($P = 0.182$; Figure 3C). Similar results were obtained in the subgroup of T4bN2 patients, for which the corresponding 5-year CSS rates were 19.1%, 23.7% and 23.3% ($P = 0.191$; Figure 3D).

Univariate analysis of data from the subgroup of T4bN0M0 subjects identified the following factors as associated with CSS: tumor size ($P = 0.024$), number of lymph nodes harvested ($P = 0.029$) and age at diagnosis ($P = 0.002$). Multivariate analysis identified tumor size ($P = 0.048$) and age at diagnosis ($P = 0.004$) as independent prognostic factors. Relative to patients with tumors $\leqslant 4.0$ cm, patients with tumors 4.0-7.0 cm were not likely to have a significantly different CSS (HR = 0.790, 95%CI: 0.554-1.127; $P = 0.194$), while patients with tumors $\geqslant 7.0$ cm were more likely to show higher CSS (HR = 0.656, 95%CI: 0.464-0.926; $P = 0.017$) (Table 4).

Table 3 Univariate and multivariate survival analyses of patients from the Surveillance, Epidemiology and End Results database with T4bN0-2M0 colon cancer

Variable	Univariate analysis		Multivariate analysis		
	5-yr CSS	*P* value	HR	95%CI	*P* value
Sex		0.404			NI
Male	46.7%				
Female	49.1%				
Year of diagnosis		0.339			NI
1988-1999	49.4%				
2000-2003	46.6%				
Race		0.184			NI
White	48.9%				
Black	41.1%				
Other[1]	48.6%				
Age at diagnosis (yr)		< 0.001			< 0.001
≤ 60	51.7%		1.000	reference	
> 60	44.8%		1.309	1.148-1.492	
Primary site		0.001			0.061
Right colon	45.1%		1.000	reference	
Left colon	52.9%		0.875	0.761-1.006	
Histological type		< 0.001			0.100
Adenocarcinoma	48.5%		1.000	reference	
Mucinous adenocarcinoma	49.7%		1.008	0.848-1.197	
Signet-ring cell carcinoma	17.2%		1.518	1.037-2.222	
Pathology grade		< 0.001			0.002
High	67.8%		1.000	reference	
Moderate	51.4%		1.530	1.127-2.077	
Poor	38.6%		1.729	1.258-2.376	
Undifferentiated	25.0%		2.526	1.389-4.596	
N stage		< 0.001			< 0.001
N0	69.5%		1.000	reference	
N1	43.7%		1.857	1.559-2.212	
N2	22.5%		3.600	3.056-4.239	
LNH		0.001			0.009
≤ 18	43.5%		1.000	reference	
> 18	53.2%		0.841	0.738-0.959	
Tumor size, cm		< 0.001			0.024
≤ 4.0	37.1%		1.000	reference	
4.0-7.0	47.0%		0.820	0.683-0.985	0.034
≥ 7.0	52.5%		0.775	0.645-0.932	0.007

[1]Includes Native American, Asian, Pacific Islander and Unknown. CSS: Cancer-specific survival; LNH: Number of lymph nodes harvested; NI: Not included in the multivariate survival analysis.

Table 4 Univariate and multivariate survival analyses of patients in the Surveillance, Epidemiology and End Results database with T4bN0M0 colon cancer

Variable	Univariate analysis		Multivariate analysis		
	5-yr CSS	*P* value	HR	95%CI	*P* value
Sex		0.443			NI
Male	67.7%				
Female	71.2%				
Year of diagnosis		0.473			NI
1988-1999	71.9%				
2000-2003	66.7%				
Race		0.388			NI
White	70.0%				
Black	62.2%				
Other[1]	73.0%				
Primary site		0.819			NI
Right colon	70.1%				
Left colon	68.6%				
Histological type		0.401			NI
Adenocarcinoma	69.0%				
Mucinous adenocarcinoma	72.1%				
Signet-ring cell carcinoma	40.0%				
Pathology grade		0.552			NI
High	80.6%				
Moderate	68.5%				
Poor	66.0%				
Undifferentiated	66.7%				
Age at diagnosis (yr)		0.002			0.004
≤ 60	74.1%		1.000	reference	
> 60	65.5%		1.441	1.127-1.841	
LNH		0.029			0.063
≤ 18	64.3%		1.000	reference	
> 18	75.1%		0.795	0.624-1.013	
Tumor size, cm		0.024			0.048
≤ 4.0	58.4%		1.000	reference	
4.0-7.0	69.3%		0.790	0.554-1.127	0.194
≥ 7.0	72.4%		0.656	0.464-0.926	0.017

[1]Includes Native American, Asian, Pacific Islander and Unknown. CSS: CANCER-specific survival; LNH: NUMBER of lymph nodes harvested; NI: NOT included in the multivariate survival analysis.

FUSCC dataset

This analysis included 101 patients (59 men and 42 women; Table 5). Median follow-up time was 47 mo (interquartile range, 33-62 mo). The distribution of histology types was adenocarcinoma, 87.1%; mucinous cancer, 9.9%; and signet ring cell cancer, 3.0%. The distribution of lymph node status was N0, 42.6%; N1, 33.7%; and N2, 23.8%. The rate of lymphovascular invasion was 55.6% for tumor at ≤ 4.0 cm, 30.8% and 34.1% for tumor at 4.0-7.0 cm and ≥ 7.0 cm.

The 5-year CSS across all N subtypes was 50.0% for patients with tumors ≤ 4.0 cm, 72.9% for those with tumors 4.0-7.0 cm and 77.1% for those with tumors ≥ 7.0 cm (Figure 4A). The 5-year CSS for patients was 83.0% in the T4bN0 subgroup, 60.8% in the T4bN1 subgroup and 56.8% in the T4bN2 subgroup (Figure 4B). Across all N subtypes and tumor sizes, 5-year CSS was lower in the presence of lymphovascular invasion (57.3%) than in its absence (77.5%), and it was lower in the presence of perineural invasion (55.5%) than in its absence (73.9%) (Figure 4C and D).

DISCUSSION

The TNM staging system, as recommended by the American Joint Committee on Cancer (AJCC), is instrumental in the diagnosis and prognosis prediction in many malignancies. In colorectal cancer, "T" in the TNM staging is distinct and reflects the depth of local invasion rather than absolute tumor size. In several studies, it has been proposed that tumor size can be a

Table 5 Demographics of patients from the Fudan University Shanghai Cancer Center database with T4bN0-2M0 colon cancer, according to tumor size *n* (%)

| Characteristic	Tumor size (cm)				*P* value
	Total (*n* = 101)	⩽ 4.0 (*n* = 18)	4.0-7.0 (*n* = 39)	⩾ 7.0 (*n* = 44)	
Median follow-up (mo)	49	46	51	44	
IQR	33-62	27-72	31-61	33-62	
Sex					0.582
Male	59 (58.4)	9 (50.0)	22 (56.4)	28 (63.6)	
Female	42 (41.6)	9 (50.0)	17 (43.6)	16 (36.4)	
Age at diagnosis (yr)					0.245
⩽ 60	33 (32.7)	3 (16.7)	13 (33.3)	17 (38.6)	
> 60	68 (67.3)	15 (83.3)	26 (66.7)	27 (61.4)	
Primary site					0.668
Right colon	50 (49.5)	8 (44.4)	18 (46.2)	24 (54.5)	
Left colon	51 (50.5)	10 (55.6)	21 (53.8)	20 (45.5)	
Histology type					0.262
Adenocarcinoma	88 (87.1)	16 (88.9)	35 (89.7)	37 (84.1)	
Mucinous adenocarcinoma	10 (9.9)	1 (5.6)	2 (5.1)	7 (15.9)	
Signet-ring cell carcinoma	3 (3.0)	1 (5.6)	2 (5.1)	0 (0.0)	
Pathology grade					0.567
High/Moderate	72 (71.3)	11 (61.1)	29 (74.4)	32 (72.7)	
Poor/Undifferentiated	29 (28.7)	7 (38.9)	10 (25.6)	12 (27.3)	
N stage					0.210
N0	43 (42.6)	4 (22.2)	20 (51.3)	19 (43.2)	
N1	34 (33.7)	10 (55.6)	10 (25.6)	14 (31.8)	
N2	24 (23.8)	4 (22.2)	9 (23.1)	11 (25.0)	
LNH					0.109
⩽ 18	56 (55.4)	14 (77.8)	20 (51.3)	22 (50.0)	
> 18	45 (44.6)	4 (22.2)	19 (48.7)	22 (50.0)	
Lymphovascular invasion					0.176
Positive	37 (36.6)	10 (55.6)	12 (30.8)	15 (34.1)	
Negative	64 (63.4)	8 (44.4)	27 (69.2)	29 (65.9)	
Perineural invasion					0.906
Positive	24 (23.8)	5 (27.8)	9 (23.1)	10 (22.7)	
Negative	77 (76.2)	13 (72.2)	30 (76.9)	34 (77.3)	

IQR: Interquartile range; LNH: Number of lymph nodes harvested; FUSCC: Fudan University Shanghai Cancer Centre.

useful addition to the TNM staging system for the sake of higher prognostic accuracy in colorectal cancer[19,20].

In the cohort of patients with T4bN0-2M0 colon cancer, small tumor size was associated with poor prognosis, particularly in T4bN0M0 patients, as well as with lymph node metastasis. Analysis of the FUSCC dataset suggested a possible link between small tumor size and lymphovascular invasion. Since lymph node involvement and lymphovascular invasion were associated with poor survival, our results suggest that small tumor size in T4b patients may reflect a more biologically aggressive phenotype. The association between tumor size and CSS appeared as a non-significant trend in the subgroup of T4bN1 patients, which may reflect the small sample size. Similarly, this association was not significant in the subgroup of T4bN2 patients, which may reflect the extensive involvement of lymph nodes, which likely influences patient survival to a greater extent than tumor size. Another factor that may explain our observed associations is that clinicians may be more likely to treat large tumors more aggressively: multivisceral resection is associated with increased tumor size[10]. This more aggressive treatment may result in greater survival.

Multivisceral resection can improve survival, but a recent population-based study revealed that most United States patients with locally advanced adherent CRC do not undergo this procedure[21]. Our present results lead us to recommend more aggressive excision in patients with T4bN0-2M0 colon cancer whose tumors are small. We also recommend the use of multimodality therapy in patients with T4b colon cancer involving small tumors. Multimodality therapy which comprises neoadjuvant CRT, total mesorectal excision surgery, and adjuvant chemotherapy is now widely used to treat patients with locally advanced rectal cancer[22-25]. Studies suggest that neoadjuvant CRT can downstage locally advanced rectal cancer, resulting in increased resectability, improved sphincter preservation, reduced local recurrence rates, and improved survival[26,27]. Even though official guidelines do not currently recommend neoadjuvant CRT for colon cancer. Nevertheless, studies suggest that neoadjuvant CRT followed by multivisceral resection can be used to treat selected patients with locally advanced adherent colon cancer[28,29]. We advocate more extensive surgery and multimodality therapy to

Figure 4 Survival curves for T4bN0-2M0 colon cancer patients from the Fudan University Shanghai Cancer Centre database. A: Stratified by tumor size; B: Stratified by N stage; C: Stratified by lymphovascular invasion; D: Stratified by perineural invasion.

improve the poor survival currently associated with T4b colon cancer involving small tumors.

To our knowledge, this is the first published study to focus on the relationship between tumor size and CSS in T4bN0-2M0 colon cancer patients. Primary data came from the large SEER database, and they gave similar results as our own data from the FUSCC database. The fact that our results for a heterogeneous cohort of US patients drawn from populations covering a quarter of the country were similar to those for a much smaller cohort of Chinese patients from a single large cancer hospital suggests that our findings are likely to be reliable.

At the same time, our study has several limitations. Despite the large size of SEER, our stratification by tumor size and N stage led to relatively small subgroups, reducing statistical power to detect small differences. This may help explain why we failed to detect significant associations between tumor size and CSS in the subgroups of T4bN1 patients. Second, the SEER database does not include information on adjuvant therapy, comorbidities, performance status, surgical margins or pathology techniques. This limited our ability to correlate tumor size with

other patient and disease characteristics. Third, our analysis did not include T4b colon cancer patients who had unresectable tumors or who refused surgical intervention, so our results may not be generalizable to those groups.

Our results provide the first evidence that small tumor size in patients with T4bN0-2M0 colon cancer, particularly T4bN0M0 cancer, is associated with worse prognosis than large tumor size. Further colon cancer studies should look specifically at T4bN0-2M0 patients to understand the underlying genetic and molecular mechanisms that may make small tumors more dangerous in this subgroup than in other subgroups of colon cancer patients.

ACKNOWLEDGMENTS

The authors would like to thank SEER program for access to the database.

COMMENTS

Background
Smaller tumor size is generally associated with greater cancer-specific

survival (CSS) in patients with colon cancer, but this association may not hold for specific subgroups of colon cancer patients. The authors hypothesized that in patients with cancer showing heavy intestinal wall invasion without distant metastasis (T4bN0-2M0), small tumor size would correlate with more aggressive tumor behavior and therefore lower CSS.

Research frontiers
Some researchers found CSS to be lower with smaller tumors, patients with tumors 4-8 cm in size showed greater CSS relative to patients with tumors < 4 cm. Similarly, a study of stage IIA colon cancer found decreased CSS with smaller tumor size.

Innovations and breakthroughs
These results provide the first evidence that small tumor size in patients with T4bN0-2M0 colon cancer, particularly T4bN0M0 cancer, is associated with worse prognosis than large tumor size.

Applications
The association between small tumor size and poor prognosis in T4bN0-2M0 patients might improve decision-making about the potential harms and benefits of the multivisceral resection.

Peer-review
This article is well written and illustrates an interesting observation. The numbers are good and it has been statistically analyzed well.

REFERENCES

1   **Campos FG**, Calijuri-Hamra MC, Imperiale AR, Kiss DR, Nahas SC, Cecconello I. Locally advanced colorectal cancer: results of surgical treatment and prognostic factors. *Arq Gastroenterol* 2011; **48**: 270-275 [PMID: 22147133 DOI: 10.1590/S0004-28032011000400010]

2   **Koca D**, Binicier C, Oztop I, Yavuzsen T, Ellidokuz H, Yilmaz U. Prognostic factors affecting recurrence and survival in patients with locally advanced rectal cancer. *J BUON* 2012; **17**: 291-298 [PMID: 22740208]

3   **An MS**, Yoo JH, Kim KH, Bae KB, Choi CS, Hwang JW, Kim JH, Kim BM, Kang MS, Oh MK, Hong KH. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy. *World J Surg Oncol* 2015; **13**: 64 [PMID: 25889520 DOI: 10.1186/s12957-015-0488-7]

4   **Søreide K**, Søreide JA, Kørner H. Prognostic role of carcinoembryonic antigen is influenced by microsatellite instability genotype and stage in locally advanced colorectal cancers. *World J Surg* 2011; **35**: 888-894 [PMID: 21301835 DOI: 10.1007/s00268-011-0979-9]

5   **Huh JW**, Lee JH, Kim HR, Kim YJ. Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. *Am J Surg* 2013; **206**: 758-763 [PMID: 23835209 DOI: 10.1016/j.amjsurg.2013.02.010]

6   **Garcia-Granero E**, Frasson M, Pous S, Cervantes A. T4a and t4b colorectal cancer: what does this mean nowadays? *Dis Colon Rectum* 2012; **55**: e367 [PMID: 23044689 DOI: 10.1097/DCR.0b013e31826915d8]

7   **Gunderson LL**, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. *J Clin Oncol* 2010; **28**: 264-271 [PMID: 19949014 DOI: 10.1200/JCO.2009.24.0952]

8   **Mohan HM**, Evans MD, Larkin JO, Beynon J, Winter DC. Multivisceral resection in colorectal cancer: a systematic review. *Ann Surg Oncol* 2013; **20**: 2929-2936 [PMID: 23666095 DOI: 10.1245/s10434-013-2967-9]

9   **Croner RS**, Merkel S, Papadopoulos T, Schellerer V, Hohenberger W, Goehl J. Multivisceral resection for colon carcinoma. *Dis Colon Rectum* 2009; **52**: 1381-1386 [PMID: 19617748 DOI: 10.1007/DCR.0b013e3181ab580b]

10 **Nakafusa Y**, Tanaka T, Tanaka M, Kitajima Y, Sato S, Miyazaki K. Comparison of multivisceral resection and standard operation for locally advanced colorectal cancer: analysis of prognostic factors for short-term and long-term outcome. *Dis Colon Rectum* 2004; **47**: 2055-2063 [PMID: 15657654 DOI: 10.1007/s10350-004-0716-7]

11 **Park S**, Lee YS. Analysis of the prognostic effectiveness of a multivisceral resection for locally advanced colorectal cancer. *J Korean Soc Coloproctol* 2011; **27**: 21-26 [PMID: 21431093 DOI: 10.3393/jksc.2011.27.1.21]

12 **Chen YG**, Liu YL, Jiang SX, Wang XS. Adhesion pattern and prognosis studies of T4N0M0 colorectal cancer following en bloc multivisceral resection: evaluation of T4 subclassification. *Cell Biochem Biophys* 2011; **59**: 1-6 [PMID: 20740326 DOI: 10.1007/s12013-010-9106-z]

13 **Kornprat P**, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Langner C. Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. *Am J Clin Oncol* 2011; **34**: 43-49 [PMID: 20101166 DOI: 10.1097/COC.0b013e3181cae8dd]

14 **Saha S**, Shaik M, Johnston G, Saha SK, Berbiglia L, Hicks M, Gernand J, Grewal S, Arora M, Wiese D. Tumor size predicts long-term survival in colon cancer: an analysis of the National Cancer Data Base. *Am J Surg* 2015; **209**: 570-574 [PMID: 25601557 DOI: 10.1016/j.amjsurg.2014.12.008]

15 **Moghimi-Dehkordi B**, Safaee A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. *Int J Colorectal Dis* 2008; **23**: 683-688 [PMID: 18330578 DOI: 10.1007/s00384-008-0463-7]

16 **Takahashi T**, Kato T, Kodaira S, Koyama Y, Sakabe T, Tominaga T, Hamano K, Yasutomi M, Ogawa N. Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy. *Am J Clin Oncol* 1996; **19**: 408-415 [PMID: 8677916 DOI: 10.1097/00000421-199608000-00019]

17 **Wang Y**, Zhuo C, Shi D, Zheng H, Xu Y, Gu W, Cai S, Cai G. Unfavorable effect of small tumor size on cause-specific survival in stage IIA colon cancer, a SEER-based study. *Int J Colorectal Dis* 2015; **30**: 131-137 [PMID: 25392257 DOI: 10.1007/s00384-014-2056-y]

18 **Camp RL**, Dolled-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res* 2004; **10**: 7252-7259 [PMID: 15534099 DOI: 10.1158/1078-0432.CCR-04-0713]

19 **Poritz LS**, Sehgal R, Hartnett K, Berg A, Koltun WA. Tumor volume and percent positive lymph nodes as a predictor of 5-year survival in colorectal cancer. *Surgery* 2011; **150**: 649-655 [PMID: 22000176 DOI: 10.1016/j.surg.2011.07.049]

20 **Balta AZ**, Özdemir Y, Sücüllü İ, Derici ST, Bağcı M, Demirel D, Akın ML. Can horizontal diameter of colorectal tumor help predict prognosis? *Ulus Cerrahi Derg* 2014; **30**: 115-119 [PMID: 25931910 DOI: 10.5152/ucd.2014.2701]

21 **Govindarajan A**, Fraser N, Cranford V, Wirtzfeld D, Gallinger S, Law CH, Smith AJ, Gagliardi AR. Predictors of multivisceral resection in patients with locally advanced colorectal cancer. *Ann Surg Oncol* 2008; **15**: 1923-1930 [PMID: 18473145 DOI: 10.1245/s10434-008-9930-1]

22 **Rau B**, Hohenberger P, Gellermann J, Hünerbein M, Hildebrandt B, Schneider U, Riess H, Wust P, Schlag PM. [T4 rectal carcinoma. Surgical and multimodal therapy]. *Chirurg* 2002; **73**: 147-153 [PMID: 11974478 DOI: 10.1007/s00104-001-0373-5]

23 **Aschele C**, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. *J Clin Oncol* 2011; **29**: 2773-2780 [PMID: 21606427 DOI: 10.1200/JCO.2010.34.4911]

24 **Rödel C**, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R. Preoperative chemoradiotherapy

and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol* 2012; **13**: 679-687 [PMID: 22627104 DOI: 10.1016/S1470-2045(12)70187-0]

25   **Sauer R**, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004; **351**: 1731-1740 [PMID: 15496622 DOI: 10.1056/NEJMoa040694]

26   **Ortholan C**, Francois E, Thomas O, Benchimol D, Baulieux J, Bosset JF, Gerard JP. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials. *Dis Colon Rectum* 2006; **49**: 302-310 [PMID: 16456638 DOI: 10.1007/s10350-005-0263-x]

27   **Rödel C**, Grabenbauer GG, Schick C, Papadopoulos T, Hohenberger W, Sauer R. Preoperative radiation with concurrent 5-fluorouracil for locally advanced T4-primary rectal cancer. *Strahlenther Onkol* 2000; **176**: 161-167 [PMID: 10812388 DOI: 10.1007/s000660050051]

28   **Hallet J**, Zih FS, Lemke M, Milot L, Smith AJ, Wong CS. Neoadjuvant chemoradiotherapy and multivisceral resection to optimize R0 resection of locally recurrent adherent colon cancer. *Eur J Surg Oncol* 2014; **40**: 706-712 [PMID: 24534363 DOI: 10.1016/j.ejso.2014.01.009]

29   **Cukier M**, Smith AJ, Milot L, Chu W, Chung H, Fenech D, Herschorn S, Ko Y, Rowsell C, Soliman H, Ung YC, Wong CS. Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: a single institution experience. *Eur J Surg Oncol* 2012; **38**: 677-682 [PMID: 22632848 DOI: 10.1016/j.ejso.2012.05.001]

Baishideng®